Insider Financial Publishes New Research On Three Promising Biotechs

Insider Financial, a leading research site for microcap companies, publishes new research on Arch Therapeutics Inc (OTCBB:ARTH), Medifirst Solutions Inc (OTCMKTS:MFST), and Cellceutix Corp (OTCMKTS:CTIX).

A Market Overreaction On Arch Therapeutics Inc (OTCBB:ARTH)

The market has overreacted by quite a bit on Arch Therapeutics Inc (OTCBB:ARTH) after the latest SEC filing. Shares dropped more than 25% on the filing of the prospectus related to the securities purchased on May 26, 2016. These shares include the 9,418,334 shares of issued and outstanding Common Stock currently and 7,063,748 shares of Common Stock currently underlying Series E Warrants for a combined total of 16,482,082 shares. The purpose of this article is to clear up the misconceptions that Mr Market may have.

For one, the filing was routine. The company was obligated to file with the Securities and Exchange Commission within 45 days after the closing of the 2016 Private Placement Financing one or more registration statements to register the shares of Common Stock issued in the Closings and the Series E Warrant Shares. If Arch Therapeutics failed to do so, the company would have faced monetary penalties to the investors that purchased these securities.

Read the Full Report on Arch Therapeutics Inc (OTCBB:ARTH) at InsiderFinancial.com

http://www.insiderfinancial.com/a-market-overreaction-on-arch-therapeutics-inc-otcbbarth/116340/

Medifirst Solutions Inc (OTCMKTS:MFST) Is All About Timing

Medifirst Solutions Inc (OTCMKTS:MFST) closed out Tuesday’s session for a 36% gain on the day’s open, and without any major updates released, the gains can only derive from one of two things. The first, that the similarity of its ticker to tech giant Microsoft Corporation (NASDAQ:MSFT) has translated to some confused buying – yes, this happens. The second, that somebody, somewhere has an inside line on Medifirst’s lead FDA 510(k) submission.

Let’s assume it’s the second one.

The submission relates to its laser technology, and the company expects an FDA decision this month. That certain interested parties might know something wider markets don’t isn’t too far fetched a theory, and would certainly explain a market cap run up to the tune of more than one third of the company’s market capitalization.

Read the Full Report on Medifirst Solutions Inc (OTCMKTS:MFST) at InsiderFinancial.com

http://www.insiderfinancial.com/medifirst-solutions-inc-otcmktsmfst-is-all-about-timing/116285/

Cellceutix Corp (OTCMKTS:CTIX) Is Setting Up For NewGen Antibiotic Gains

Massachusetts based Cellceutix Corp (OTCMKTS:CTIX) had a pretty tough second quarter, falling from April highs of $1.84 to current levels at circa $1.20. Across the period, however, no real company updates hit press, and it looks as though wider market sentiment played the major role in the decline. There’s a good chance, therefore, that as sentiment shifts, Cellceutix could pick up some upside momentum. Add to this chance that the company is about to kick off a pivotal trial in its lead candidate, a new generation antibiotic called Brilacidin, and it seems well worth a look.

Back in 2013, Cellceutix picked up the rights to Brilacidin in an asset sale on the back of a company called PolyMedix going bankrupt. At that point, it had just completed a phase 2a, and was heading into a pre-pivotal 2b. Cellceutix got its hands on Brilacidin for $5 million, which now looks like a bargain acquisition. Why? Because Merck picked up the rights to what is essentially the only comparable drug on the market – Cubicin – a couple of years later in an acquisition valued at $9.5 billion.

Cellceutix has spent the last two years proving that Brilacidin is comparable to Cubicin, which it has done successfully by way of a phase 2b, and to boot, it’s shown equivalence with a single dose, while Merck’s candidate requires a 7-day treatment period.

Read the Full Report on Cellceutix Corp (OTCMKTS:CTIX) at InsiderFinancial.com

http://www.insiderfinancial.com/cellceutix-corp-otcmktsctix-is-setting-up-for-newgen-antibiotic-gains/116282/

Insider Financial

Insider Financial is a leading research site for microcap companies. We specialize in finding tomorrow’s microcap runner ahead of the crowd. We look for undervalued and mispriced securities as well as today’s small caps that can grow into tomorrow’s mid cap and large cap leaders.

Disclosure

Insider Financial is a wholly-owned subsidiary of Archangel Media Consulting, LLC. Remember always participate at your own risk. Our profiles are based on research that we have done and do not provide any warranties. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. We have no position in ARTH, MFST, and CTIX. We have not been compensated for this report.

Contact

Insider Financial - http://www.insiderfinancial.com/

Email - editor@insiderfinancial.com

Twitter - https://twitter.com/InsidrFinancial

Insider Financial

3675 Rainbow Blvd Suite #107-639

Las Vegas , NV 89103

Arch Therapeutics (QB) (USOTC:ARTH)
過去株価チャート
から 11 2024 まで 12 2024